| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses.
|
J Dent Res
|
2006
|
2.56
|
|
2
|
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours.
|
Br J Cancer
|
2007
|
2.15
|
|
3
|
111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.
|
Eur J Cancer
|
2007
|
2.07
|
|
4
|
A potential role of macrophage activation in the treatment of cancer.
|
Crit Rev Oncol Hematol
|
2002
|
1.81
|
|
5
|
Prognostic versus predictive value of biomarkers in oncology.
|
Eur J Cancer
|
2008
|
1.65
|
|
6
|
Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.
|
J Med Genet
|
2002
|
1.57
|
|
7
|
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.
|
Br J Cancer
|
2009
|
1.53
|
|
8
|
Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study.
|
Ann Oncol
|
2004
|
1.52
|
|
9
|
Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer.
|
Gut
|
2006
|
1.46
|
|
10
|
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
|
Ann Oncol
|
2010
|
1.35
|
|
11
|
The clinical trail of TRAIL.
|
Eur J Cancer
|
2006
|
1.35
|
|
12
|
Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination.
|
Oncogene
|
2012
|
1.31
|
|
13
|
Molecular imaging of breast cancer.
|
Breast
|
2009
|
1.22
|
|
14
|
MEIS and PBX homeobox proteins in ovarian cancer.
|
Eur J Cancer
|
2007
|
1.19
|
|
15
|
Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer.
|
Cancer Treat Rev
|
2003
|
1.19
|
|
16
|
Genetic factors influencing pyrimidine-antagonist chemotherapy.
|
Pharmacogenomics J
|
2005
|
1.18
|
|
17
|
Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic.
|
Crit Rev Oncol Hematol
|
2006
|
1.16
|
|
18
|
The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer.
|
Br J Cancer
|
2008
|
1.15
|
|
19
|
The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours.
|
Eur J Cancer
|
2004
|
1.14
|
|
20
|
Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus.
|
Ann Rheum Dis
|
2004
|
1.13
|
|
21
|
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.
|
Br J Cancer
|
2006
|
1.12
|
|
22
|
Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis.
|
Endocr Relat Cancer
|
2005
|
1.12
|
|
23
|
TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives.
|
Drug Resist Updat
|
2009
|
1.11
|
|
24
|
Multidrug resistance related molecules in human and murine lung.
|
J Clin Pathol
|
2002
|
1.10
|
|
25
|
Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer.
|
Ann Oncol
|
2006
|
1.08
|
|
26
|
Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature.
|
Crit Rev Oncol Hematol
|
2003
|
1.08
|
|
27
|
Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study.
|
Gynecol Oncol
|
2005
|
1.08
|
|
28
|
Diagnostic, surgical and medical aspect of the midgut carcinoids.
|
Cancer Treat Rev
|
2002
|
1.08
|
|
29
|
[The role of trastuzumab in mammary carcinoma in The Netherlands].
|
Ned Tijdschr Geneeskd
|
2006
|
1.07
|
|
30
|
Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center cohort.
|
Gynecol Oncol
|
2007
|
1.01
|
|
31
|
PET imaging of steroid receptor expression in breast and prostate cancer.
|
Curr Pharm Des
|
2008
|
0.98
|
|
32
|
Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease.
|
Int J Gynecol Cancer
|
2005
|
0.96
|
|
33
|
Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy.
|
Int J Gynecol Cancer
|
2006
|
0.95
|
|
34
|
Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination.
|
Eur J Cancer
|
2006
|
0.95
|
|
35
|
Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas.
|
Histopathology
|
2004
|
0.95
|
|
36
|
First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial.
|
Br J Cancer
|
2003
|
0.93
|
|
37
|
Changes in body composition after childhood cancer treatment: impact on future health status--a review.
|
Crit Rev Oncol Hematol
|
2007
|
0.92
|
|
38
|
Targeting TRAIL death receptors.
|
Curr Opin Pharmacol
|
2008
|
0.92
|
|
39
|
Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin.
|
Eur J Endocrinol
|
2003
|
0.92
|
|
40
|
Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation.
|
Br J Cancer
|
2004
|
0.92
|
|
41
|
Irradiation of rat brain reduces P-glycoprotein expression and function.
|
Br J Cancer
|
2007
|
0.91
|
|
42
|
Anticancer drugs aimed at E6 and E7 activity in HPV-positive cervical cancer.
|
Curr Cancer Drug Targets
|
2012
|
0.91
|
|
43
|
Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines.
|
Br J Cancer
|
2003
|
0.91
|
|
44
|
Molecular imaging: what can be used today.
|
Cancer Imaging
|
2005
|
0.90
|
|
45
|
Endothelial cell effects of cytotoxics: balance between desired and unwanted effects.
|
Cancer Treat Rev
|
2004
|
0.90
|
|
46
|
Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL.
|
Br J Cancer
|
2013
|
0.90
|
|
47
|
Guideline adherence for early breast cancer before and after introduction of the sentinel node biopsy.
|
Br J Cancer
|
2005
|
0.89
|
|
48
|
Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
|
J Clin Pathol
|
2009
|
0.89
|
|
49
|
An in vitro model for purging of tumour cells from ovarian tissue.
|
Hum Reprod
|
2004
|
0.89
|
|
50
|
Cytotoxicity of rhein, the active metabolite of sennoside laxatives, is reduced by multidrug resistance-associated protein 1.
|
Br J Cancer
|
2002
|
0.88
|
|
51
|
Long-term morbidity of adjuvant whole abdominal radiotherapy (WART) or chemotherapy for early stage ovarian cancer.
|
Eur J Cancer
|
2009
|
0.87
|
|
52
|
Dysplasia in fundic gland polyps is associated with nuclear beta-catenin expression and relatively high cell turnover rates.
|
Scand J Gastroenterol
|
2003
|
0.86
|
|
53
|
Detection of telomerase, its components, and human papillomavirus in cervical scrapings as a tool for triage in women with cervical dysplasia.
|
J Clin Pathol
|
2003
|
0.86
|
|
54
|
Successful treatment of metastatic esthesioneuroblastoma.
|
Neth J Med
|
2003
|
0.86
|
|
55
|
Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer.
|
Ann Oncol
|
2011
|
0.86
|
|
56
|
Analysis of the entire HLA region in susceptibility for cervical cancer: a comprehensive study.
|
J Med Genet
|
2005
|
0.86
|
|
57
|
A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer.
|
Oncogene
|
2011
|
0.85
|
|
58
|
Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial.
|
Br J Cancer
|
2003
|
0.85
|
|
59
|
Improvements in small bowel carcinoid diagnosis and staging: 18F-DOPA PET, capsule endoscopy and double balloon enteroscopy.
|
Dig Liver Dis
|
2008
|
0.85
|
|
60
|
Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line.
|
Cell Death Differ
|
2003
|
0.84
|
|
61
|
The chemokine network, a newly discovered target in high grade gliomas.
|
Crit Rev Oncol Hematol
|
2010
|
0.84
|
|
62
|
A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma.
|
Gynecol Oncol
|
2005
|
0.83
|
|
63
|
Paclitaxel and carboplatin concurrent with radiotherapy for primary cervical cancer.
|
Anticancer Res
|
2004
|
0.83
|
|
64
|
Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer.
|
Gynecol Oncol
|
2002
|
0.83
|
|
65
|
Long-term cardiac follow-up in survivors of a malignant bone tumour.
|
Ann Oncol
|
2006
|
0.83
|
|
66
|
Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1.
|
Br J Cancer
|
2007
|
0.83
|
|
67
|
A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer.
|
Eur J Cancer
|
2005
|
0.83
|
|
68
|
Factors influencing haematological recovery following high-dose chemotherapy and peripheral stem-cell transplantation for haematological malignancies; 1-year analysis.
|
Eur J Cancer
|
2004
|
0.82
|
|
69
|
A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours.
|
Br J Cancer
|
2004
|
0.82
|
|
70
|
Indomethacin-induced activation of the death receptor-mediated apoptosis pathway circumvents acquired doxorubicin resistance in SCLC cells.
|
Br J Cancer
|
2005
|
0.82
|
|
71
|
Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy; cardiovascular risk factors and signs of vascular damage.
|
Eur J Cancer
|
2004
|
0.81
|
|
72
|
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours.
|
Br J Cancer
|
2012
|
0.81
|
|
73
|
Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies.
|
Br J Pharmacol
|
2012
|
0.81
|
|
74
|
The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium.
|
J Clin Pathol
|
2002
|
0.81
|
|
75
|
Debulking surgery for ovarian epithelial cancer performed by a gynaecological oncologist improved survival compared with less specialised surgeons.
|
Cancer Treat Rev
|
2006
|
0.81
|
|
76
|
Regulation of TRAIL receptor expression by β-catenin in colorectal tumours.
|
Carcinogenesis
|
2013
|
0.80
|
|
77
|
Effect of tamoxifen on the endometrium and the menstrual cycle of premenopausal breast cancer patients.
|
Int J Gynecol Cancer
|
2009
|
0.80
|
|
78
|
Inhibition of formyl peptide receptor in high-grade astrocytoma by CHemotaxis Inhibitory Protein of S. aureus.
|
Br J Cancer
|
2013
|
0.80
|
|
79
|
Portal and systemic serum growth factor and acute-phase response after laparotomy or partial hepatectomy in patients with colorectal liver metastases: a prognostic role for C-reactive protein and hepatocyte growth factor.
|
Scand J Gastroenterol
|
2004
|
0.80
|
|
80
|
Quantification of oral mucositis due to radiotherapy by determining viability and maturation of epithelial cells.
|
J Oral Pathol Med
|
2002
|
0.79
|
|
81
|
Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma.
|
Gynecol Oncol
|
2004
|
0.79
|
|
82
|
Changes in bile acid composition and effect on cytolytic activity of fecal water by ursodeoxycholic acid administration: a placebo-controlled cross-over intervention trial in healthy volunteers.
|
Scand J Gastroenterol
|
2002
|
0.79
|
|
83
|
Treatment of cervical cancer.
|
Lancet
|
2002
|
0.78
|
|
84
|
Microenvironment involved in FPR1 expression by human glioblastomas.
|
J Neurooncol
|
2015
|
0.78
|
|
85
|
Calcium affects biomarkers of colon carcinogenesis after right hemicolectomy.
|
Eur J Clin Invest
|
2002
|
0.77
|
|
86
|
Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.
|
Anticancer Drugs
|
2002
|
0.77
|
|
87
|
[The value of gene expression profiles using micoarrays for the individualisation of adjuvant therapy after surgery for breast cancer].
|
Ned Tijdschr Geneeskd
|
2005
|
0.76
|
|
88
|
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).
|
Ann Oncol
|
2016
|
0.75
|
|
89
|
[Treatment of patients with differentiated thyroid carcinoma].
|
Ned Tijdschr Geneeskd
|
2002
|
0.75
|
|
90
|
Relevance of high-dose chemotherapy in solid tumours.
|
Cancer Treat Rev
|
2005
|
0.75
|
|
91
|
[Gastroenteropancreatic neuroendocrine tumours (carcinoid tumours): definition, clinical aspects, diagnosis and therapy].
|
Ned Tijdschr Geneeskd
|
2006
|
0.75
|
|
92
|
Heterogeneity in simvastatin-induced cytotoxicity in AML is caused by differences in Ras-isoprenylation.
|
Leukemia
|
2011
|
0.75
|
|
93
|
Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients.
|
Bone Marrow Transplant
|
2008
|
0.75
|
|
94
|
No association between the Arg201Gly polymorphism of the DCC gene and colorectal cancer.
|
Dig Liver Dis
|
2004
|
0.75
|
|
95
|
Clinical cancer research 2002: new agents and therapies.
|
Drug Resist Updat
|
2002
|
0.75
|
|
96
|
Neuropsychological investigation into the carcinoid syndrome.
|
Psychopharmacology (Berl)
|
2003
|
0.75
|
|
97
|
Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group.
|
Ann Oncol
|
2002
|
0.75
|
|
98
|
Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755.
|
Cancer Chemother Pharmacol
|
2004
|
0.75
|
|
99
|
Hemodialysis no reason to withhold everolimus.
|
Cancer Chemother Pharmacol
|
2012
|
0.75
|